文献速递肿瘤 PET/CT核素与放射性配体治疗

临床前肝转移模型中使用[64/67Cu]Cu-SARTATE检测与治疗神经母细胞瘤微小残留病

Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases.
PubMed 文献 · EJNMMI Res · 2021-02-25

在神经母细胞瘤肝转移裸鼠模型中,[64Cu]Cu-SARTATE PET显像可确认肿瘤摄取并快速清除,[67Cu]Cu-SARTATE在接种后2周给药可延长生存,4周给药未见显著疗效。

要点

  • SSTR2靶向的[64/67Cu]Cu-SARTATE诊疗对可检测并治疗神经母细胞瘤MRD。
  • 接种后2周给予[67Cu]Cu-SARTATE较对照组平均延长生存13天(30%),p=0.012。
  • 接种后4周给药未观察到显著治疗效应(p=0.064)。

核心结论

  • 本研究在临床前肝转移模型中证实[64/67Cu]Cu-SARTATE诊疗对用于SSTR2阳性神经母细胞瘤MRD检测与治疗的潜力。

研究设计与样本

  • 使用IMR32细胞在裸鼠中建立肝转移性神经母细胞瘤MRD模型。
  • 以小动物PET和离体组织分析测定[64Cu]Cu-SARTATE的生物分布。
  • 生存研究将小鼠(每组6-8只)在接种后2周或4周单次给予生理盐水、9.25 MBq(250 µCi)或18.5 MBq(500 µCi)[67Cu]Cu-SARTATE。

主要发现

  • PET显像和离体生物分布证实[64Cu]Cu-SARTATE肿瘤摄取并快速从其他组织清除。
  • 主要清除器官为肾脏,注射后24小时为15.6 ± 5.8% IA/g,48小时为11.5 ± 2.8% IA/g(n=3/4)。
  • 放射自显影和组织学分析证实[64Cu]Cu-SARTATE在存活、SSTR2阳性肿瘤区域摄取,24小时平均肿瘤摄取为14.1-25.0% IA/g。
  • 接种后2周开始[67Cu]Cu-SARTATE治疗较未治疗组平均延长生存13天(30%):对照组平均生存43.0 ± 8.1天 vs. 治疗组55.6 ± 9.1天,p=0.012。
  • 接种后4周开始[67Cu]Cu-SARTATE治疗未观察到显著治疗效应:对照组14.6 ± 8.5天,9.25 MBq组9.5 ± 1.6天,18.5 MBq组15.6 ± 4.1天,p=0.064。

临床怎么用

  • 该临床前结果支持进一步探索[64/67Cu]Cu-SARTATE诊疗对用于SSTR2阳性神经母细胞瘤MRD的检测与治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A major challenge to the long-term success of neuroblastoma therapy is widespread metastases that survive initial therapy as minimal residual disease (MRD). The SSTR2 receptor is expressed by most neuroblastoma tumors making it an attractive target for molecularly targeted radionuclide therapy. SARTATE consists of octreotate, which targets the SSTR2 receptor, conjugated to MeCOSar, a bifunctional chelator with high affinity for copper. Cu-SARTATE offers the potential to both detect and treat neuroblastoma MRD by using [64Cu]Cu-SARTATE to detect and monitor the disease and [67Cu]Cu-SARTATE as the companion therapeutic agent. In the present study, we tested this theranostic pair in a preclinical model of neuroblastoma MRD. An intrahepatic model of metastatic neuroblastoma was established using IMR32 cells in nude mice. The biodistribution of [64Cu]Cu-SARTATE was measured using small-animal PET and ex vivo tissue analysis. Survival studies were carried out using the same model: mice (6-8 mice/group) were given single doses of saline, or 9.25 MBq (250 µCi), or 18.5 MBq (500 µCi) of [67Cu]Cu-SARTATE at either 2 or 4 weeks after tumor cell inoculation. RESULTS: PET imaging and ex vivo biodistribution confirmed tumor uptake of [64Cu]Cu-SARTATE and rapid clearance from other tissues. The major clearance tissues were the kidneys (15.6 ± 5.8% IA/g at 24 h post-injection, 11.5 ± 2.8% IA/g at 48 h, n = 3/4). Autoradiography and histological analysis confirmed [64Cu]Cu-SARTATE uptake in viable, SSTR2-positive tumor regions with mean tumor uptakes of 14.1-25.0% IA/g at 24 h. [67Cu]Cu-SARTATE therapy was effective when started 2 weeks after tumor cell inoculation, extending survival by an average of 13 days (30%) compared with the untreated group (mean survival of control group 43.0 ± 8.1 days vs. 55.6 ± 9.1 days for the treated group; p = 0.012). No significant therapeutic effect was observed when [67Cu]Cu-SARTATE was started 4 weeks after tumor cell inoculation, when the tumors would have been larger (control group 14.6 ± 8.5 days; 9.25 MBq group 9.5 ± 1.6 days; 18.5 MBq group 15.6 ± 4.1 days; p = 0.064). CONCLUSIONS: Clinical experiences of peptide-receptor radionuclide therapy for metastatic disease have been encouraging. This study demonstrates the potential for a theranostic approach using [64/67Cu]Cu-SARTATE for the detection and treatment of SSTR2-positive neuroblastoma MRD.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Dearling JLJ, van Dam EM, Harris MJ, et al. Detection and therapy of neuroblastoma minimal residual disease using [64/67Cu]Cu-SARTATE in a preclinical model of hepatic metastases. EJNMMI Res. 2021. PMID: 33630166. doi:10.1186/s13550-021-00763-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。